{"entity":{"id":"nct07151872","kind":"trial","name":"Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer","aka":[],"tldr":"A phase 2 trial of gemcitabine, cisplatin, oxaliplatin and capecitabine in gallbladder cancer and other biliary tract cancers, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.","summary":"Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer is a phase 2 interventional study registered as NCT07151872 by Qilu Pharmaceutical Co., Ltd., with a registry enrolment figure of 120 participants, started 2025-09 and due to reach its primary completion in 2026-10. Interventions recorded: QLS31905 for Injection, Gemcitabine Hydrochloride for Injection, Cisplatin for Injection, QL2107 Injection, Oxaliplatin Injection, Capecitabine Tablets. Conditions listed: CLDN18.2-positive Advanced Biliary Tract Cancer. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07151872","url":"https://clinicaltrials.gov/study/NCT07151872"}],"tags":["ctgov-ingest","gallbladder-deep-dive"],"related":[],"cancers":["gallbladder","cholangiocarcinoma","biliary-tract-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["gemcitabine","cisplatin","oxaliplatin","capecitabine"],"companies":["qilu-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07151872","phase":"2","setting":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of QLS31905 for Injection in Combination With Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer","sponsor":"Qilu Pharmaceutical Co., Ltd.","participation":[{"nct":"NCT07151872","source":"https://clinicaltrials.gov/study/NCT07151872","fetchedAt":"2026-10-07T16:55:29.886Z","studySha256":"949d192b6ac47fb7e1b33ee2fdd7249faa6f47a1471f16c32354e214f3c7eba4","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2025-09-03","leadSponsor":"Qilu Pharmaceutical Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":120,"enrolmentType":"ESTIMATED","siteCount":0,"recruitingSiteCount":0}],"started":"2025-09","startedType":"estimated","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07151872/","neighbours":{"cancer":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"}],"company":[{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/"}],"term":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}